• Like

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Vitro Biopharma-Business & technical overview 12 9-13


Overview of Business Strategy and Stem Cell Research and Regenerative Medicine Solutions

Overview of Business Strategy and Stem Cell Research and Regenerative Medicine Solutions

Published in Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Technical and Business Overview December 9, 2013 By Jim Musick, Ph.D. President & CEO
  • 2. Location of Golden, CO Facility
  • 4. The Vitro Management Team James R Musick, Ph.D, President, CEO & Chairman of the Board Pete Shuster, Director Duane Knight, CPA, SAB Joe Nieusma, Ph.D., SAB Pamela Rice, Ph.D., SAB
  • 5. Team Vitro Partners & Collaborators Neuromics, Inc. Merger candidate/distributor James Posillico, PhD. FSH Patent Licensee Sean Marconi IR/PR & Social Media HemoGenix, Inc. LUMENESC Assay Labs Inc. CRO/Flow cytometry collaboration CCNY Professor Lane Gilcrest: Research Collaboration Celartia, Inc. Distributor
  • 6. STEM CELL PRODUCTS Focus on Mesenchymal Stem Cells • Numerous Clinical Uses: Joint disease & injury, autoimmunity, stroke, organ failure (heart, liver, kidney & lung), MS, promotion of HSC engraftment, regenerative medicine, cancer, hearing loss, etc. • Readily Available: Blood, adipose (fat) tissue, bone marrow, teeth, etc
  • 7. GFP-Expressing Human MSCs Catalog Number SC00A4 Fluorescent Image of Single Human MSC
  • 8. MSC Growth in Low Serum MSCGro™ Compared to Lonza MSC-GM MSCGroTM at Day 3 Lonza at Day 3 MSCGroTM at Day 4 Lonza at Day 4
  • 9. Human MSC Growth in MSCGroTM vs Competitors Media: MSCGroTM results in faster growth & 2-3-fold greater cell recovery
  • 10. 160 Real Time Stability of MSCGro Compared to Competitor's Medium 140 Doubling Time (Hrs) 120 MSCGro 100 at 5% O2 MSCM-ScienCell at 5% O2 80 MSCGro at 20% O2 (Adipose MSCs by third party) 60 40 20 0 0 1 2 3 4 5 6 7 8 9 o Months at 2-8 C 10 11 12 13 14
  • 11. Competitive Advantages of MSCGroTM • MSC growth rate/cell recovery > Lonza, InVitrogen, Stem Cell Technologies, ScienCell & ZenBio media. • MSC quality/potency (Lumenesc™) > Lonza, InVitrogen and Stem Cell Technologies media. • Vastly improved real time stability. • Medium function unaffected by freezing. • Out-performs competitors at both reduced & ambient O2 • Supports self-renewal of human, rat & mouse MSCs • Also supports primary cultures: fibroblasts (human & rat); rat cardiomyocytes & possibly hepatocytes • Provided complete & ready to use as is.
  • 12. Neuromics, Inc. Research Products Wide range of Research Products (2500 total) • Antibodies & proteins • Stem cell-based products • Primary cells • Cell-based assays • Molecular Biology Products
  • 13. Drug Discovery and Development Overview • Problems with current discovery technology: High failure rate; side-effects • Advantages of stem cell-derived systems: Reduce false positives in animal systems High specificity due to biological targeting Cost-effective, high-throughput, automatic • Market Size & Strategic Plan
  • 14. Need and Market for Osteoporosis Drugs • Osteoporosis is a growing, top-10 global disease • Market ~ $11 billion USD by 2015. • Anti-resorptive drugs block osteocylasts & bone loss • Pathology is age and/or hormone-induced impaired osteogenesis. • New anabolic drugs induce bone growth and decreased fracture risk. • Current anabolic drugs have side effects & must be discontinued after two years use.
  • 15. Osteoporosis Drug Discovery: Cell-Based Assay
  • 16. Osteoporosis Drug Pipeline Sponsor Drug Target Phase Amgen Romosozumab SOST neutralization III Amgen AMG 167 SOST Neutralization I Lilly Blososumab SOST Neutralization II Lilly LY2874455* FGFR Anatagonist II Merck MK-0822 (Odanacatib) Cathepsin K inhibitor III Takada NE-58095 (risedronate) Osteoclast inhibitor III Lexicon Pharmaceuticals LP533401 5-HT Synthesis inhibition I * Approval sought for non-osteoporosis indication
  • 17. Stem Cell Regenerative Medicine • Market description • Market Size • Strategy and Status Wound care products Muscular skeletal targets: Osteoarthritis, bone regeneration, ligament/tendon repair
  • 18. Intellectual Property • Issued & Pending Patents: – – – – FSH Production/generation; Adult stem cell generation, iPSCs without transfection, Regenerative medicine materials & procedures. • Strategy to increase competitive advantages & FTO